United States Patent and Trademark Office
- Sales Receipt -

10/17/2005 DWILLIA4 00000005 024035 10070954

01 FC:1202 550.00 DA



## THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: ARKINSTALL=1

In re Application of:

Stephen ARKINSTALL et al

Appln. No.: 10/070,954

Appln. No.: 10/070,954

Filed: July 22, 2002

Washington, D.C.

For: PHARMACEUTICALLY ACTIVE

SULFONAMIDE DERIVATIVES

Art Unit: 1614

Examiner: Brenda L. Coleman

Washington, D.C.

## REPLY: AMENDMENT AND REMARKS

Honorable Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window
Randolph Building, Mail Stop Amendment
401 Dulany Street
Alexandria, VA 22314

Sir:

Replying to the Office Action mailed July 5, 2005, please amend as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 34 of this paper.

Attached is a print out from Vasudha Pharm Chem. Ltd. following page 42 of this paper.

Appln. No. 10/070,954 Amd. dated September 30, 2005 Reply to Office Action of July 5, 2005

This rejection is respectfully traversed.

Application 10/381,665 has not yet been examined. There is no way of knowing what claims in 10/381,665 will eventually be allowed. It is thus respectfully submitted that a provisional obviousness-type double patenting rejection is premature.

## Election/Restriction

Claim 4 has been withdrawn from consideration.

Claims 3 and 13 have been amended to delete the nonelected compounds.

In view of the above, it is respectfully submitted that the claims are now in condition for allowance, and favorable action thereon is earnestly solicited.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C. Attorneys for Applicant

By:

Anne M. Kornbau

Registration No. 25,884

AMK:srd

Telephone No.: (202) 628-5197
Facsimile No.: (202) 737-3528
G:\BN\S\Ser1\Arkinstall1\PTO\AMD 30 SEP 05.doc

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ARKINSTALL, et al.

Application 18ADE 010.954

Filed: July 22, 2002

FOR PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES

Art Unit: 1614

Examiner: Brenda L. Coleman

Washington, D.C.

Atty.'s Docket: ARKINSTALL=1

OR

OR

Date: September 30, 2005

THE COMMISSIONER OF PATENTS U.S. Patent and Trademark Office **Customer Service Window** Randolph Building, Mail Stop Amendment 401 Dulany Street Alexandria, VA 22314

Confirmation No. 4903

Sir.

Transmitted herewith is a [XX] REPLY: AMENDMENT AND REMARKS in the aboye-identified application.

- [ ] Small Entity Status: Applicant(s) claim small entity status. See 37 C.F.R. §1.27.
- [XX] No additional fee is required.
- The fee has been calculated as shown below:

	(Col. 1)		(Col. 2)	(Col. 3)	
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA EQUALS	
TOTAL	• 41	MINUS	<b>™</b> 41	0	
INDEP.	• 3	MINUS	*** 3	0	
FIRST PR	ESENTATION OF	MULTIPLE	DEP. CLAIM		

		RATE	ADDITIONAL FEE		
	x	25	\$		
	X	100	\$		
	+	180	\$		
O	NAL	FEE TOTAL	\$		

OTHER THAN SMALL ENTITY RATE **ADDITIONAL** FEE 50 200 \$ 360 \$

- If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
- If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.
- If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Cot. 1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

[ ] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.138(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

ADDITIO

	Small Entity		Other Than Small Entity				
	Response Filed Within		Response Filed Within				
	[ ] First - \$ 60.00		[ ]	First		\$ 120.00	
	[ ] Second - \$ 225.00			Second	-	\$ 450.00	
	[ ] Third - \$ 510.00	–		Third	-	\$ 1020.00	
	[ ] Fourth - \$ 795.00		( )	Fourth	-	\$ 1590.00	
	Month After Time Period Set		Month After Time Period Set				
	[ ] Less fees (\$) already paid for months		-				
[ ]	Please charge my Deposit Account No. 02-4035 in the ar	mount of \$	·				
[ ]	Credit Card Payment Form, PTO-2038, is attached, authorizing payment in the amount of \$						
[ ]	A check in the amount of \$ is attached	(check no. ).					
[XX]	The Commissioner is hereby authorized and requested to	o charge any additional fe	es whi	ch may be i	equ	ired in conn	

nection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1,18.

BROWDY AND NEIMARK, P.L.L.C.

Attorneys for Applicant(s)

nne M. Korkbau

Facsimile: (202) 737-3528 Telephone: (202) 628-5197

Registration No. 25,884